Profile - To The Moon

LimLK

Posts · 7Posts · 7
Following · 0Following · 0
Followers · 0Followers · 0

- LimLKLimLK
  ·2022-01-14
  Up up up, hope we can travel soon
  Airline stocks jumped in morning trading
  Airline stocks jumped in morning trading. Delta Air Lines,Southwest Airlines,United Continental and
  Airline stocks jumped in morning trading
  273 Comment
  2
  Share
  Report
- LimLKLimLK
  ·2022-01-13
  Up up up
  Wall Street Closes Higher as Inflation Data Supports Fed Bets
  U.S. stock indexes rose on Wednesday after data showed that while U.S. inflation was at its highest
  Wall Street Closes Higher as Inflation Data Supports Fed Bets
  198 Comment
  5
  Share
  Report
- LimLKLimLK
  ·2022-01-11
  Like roller coasters having up and down with unpredictable changes
  Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky
  Who needs parody cryptocurrency when car stocks are this exciting?
  Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky
  323 Comment
  Like
  Share
  Report
- LimLKLimLK
  ·2022-01-10
  Hope we can have an vaccine for all variants to last longer rather than many jabs within 1 year
  3 Big FDA Approvals to Watch for in Q1 2022
  Some of the world's biggest drugmakers have important dates with the FDA coming up soon.
  3 Big FDA Approvals to Watch for in Q1 2022
  261 Comment
  Like
  Share
  Report
- LimLKLimLK
  ·2022-01-09
  Hope Covid will end this year
  3 COVID Stocks That Will Make Billions in 2022
  These three COVID-19 stocks could rake in a tremendous amount of cash this year.
  3 COVID Stocks That Will Make Billions in 2022
  246 Comment
  4
  Share
  Report
- LimLKLimLK
  ·2022-01-07
  Hope this Covid-19 and whatever variants are over soon!
  J&J says its single dose protects against breakthrough COVID-19 for up to 6 months
  Jan 6 (Reuters) - Johnson & Johnson said on Thursday that a real-world study showed its single shot
  J&J says its single dose protects against breakthrough COVID-19 for up to 6 months
  266 Comment
  1
  Share
  Report
- LimLKLimLK
  ·2022-01-06
  Stay safe everyone and hope this will be over soon🙏
  Walmart halves paid leave for COVID-positive workers
  Jan 5 (Reuters) - Walmart Inc workers in the United States who must isolate or who have tested posit
  Walmart halves paid leave for COVID-positive workers
  428 Comment
  2
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4104063855005830","uuid":"4104063855005830","gmtCreate":1640961407779,"gmtModify":1640963881289,"name":"LimLK","pinyin":"limlk","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":11,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9002759362,"gmtCreate":1642113292591,"gmtModify":1676533681316,"author":{"id":"4104063855005830","authorId":"4104063855005830","name":"LimLK","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104063855005830","authorIdStr":"4104063855005830"},"themes":[],"htmlText":"Up up up, hope we can travel soon&nbsp;","listText":"Up up up, hope we can travel soon&nbsp;","text":"Up up up, hope we can travel soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002759362","repostId":"1105224732","repostType":4,"repost":{"id":"1105224732","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642086896,"share":"https://ttm.financial/m/news/1105224732?lang=&edition=fundamental","pubTime":"2022-01-13 23:14","market":"us","language":"en","title":"Airline stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1105224732","media":"Tiger Newspress","summary":"Airline stocks jumped in morning trading. Delta Air Lines,Southwest Airlines,United Continental and ","content":"<html><head></head><body><p>Airline stocks jumped in morning trading. <a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a>,<a href=\"https://laohu8.com/S/LUV\">Southwest Airlines</a>,<a href=\"https://laohu8.com/S/UAL\">United Continental</a> and <a href=\"https://laohu8.com/S/AAL\">American Airlines</a> rose between 2% and 5%.</p><p><img src=\"https://static.tigerbbs.com/5337c1fa70a52ef20ee586624787937c\" tg-width=\"1080\" tg-height=\"1915\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airline stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirline stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-13 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Airline stocks jumped in morning trading. <a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a>,<a href=\"https://laohu8.com/S/LUV\">Southwest Airlines</a>,<a href=\"https://laohu8.com/S/UAL\">United Continental</a> and <a href=\"https://laohu8.com/S/AAL\">American Airlines</a> rose between 2% and 5%.</p><p><img src=\"https://static.tigerbbs.com/5337c1fa70a52ef20ee586624787937c\" tg-width=\"1080\" tg-height=\"1915\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAL":"美国航空","UAL":"联合大陆航空","BK4547":"WSB热门概念","BK4008":"航空公司","BK4500":"航空公司","DAL":"达美航空","LUV":"西南航空"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105224732","content_text":"Airline stocks jumped in morning trading. Delta Air Lines,Southwest Airlines,United Continental and American Airlines rose between 2% and 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002224311,"gmtCreate":1642031235351,"gmtModify":1676533672999,"author":{"id":"4104063855005830","authorId":"4104063855005830","name":"LimLK","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104063855005830","authorIdStr":"4104063855005830"},"themes":[],"htmlText":"Up up up&nbsp;","listText":"Up up up&nbsp;","text":"Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002224311","repostId":"1190696876","repostType":4,"repost":{"id":"1190696876","kind":"news","pubTimestamp":1642028546,"share":"https://ttm.financial/m/news/1190696876?lang=&edition=fundamental","pubTime":"2022-01-13 07:02","market":"us","language":"en","title":"Wall Street Closes Higher as Inflation Data Supports Fed Bets","url":"https://stock-news.laohu8.com/highlight/detail?id=1190696876","media":"StreetInsider","summary":"U.S. stock indexes rose on Wednesday after data showed that while U.S. inflation was at its highest ","content":"<html><head></head><body><p>U.S. stock indexes rose on Wednesday after data showed that while U.S. inflation was at its highest in decades, it largely met economists&#39; expectations, cooling some fears that the Federal Reserve would have to pull back support even more forcibly than already expected.</p><p>Ten out of the 11 major S&amp;P sectors finished higher after the news with the S&amp;P 500 and the Nasdaq outperforming the Dow as growth stocks outperformed value.</p><p>Data from the Labor Department showed the consumer price index (CPI) increased 0.5% last month after rising 0.8% in November, while in the 12 months through December, the CPI surged 7.0% to its highest year-on-year rise in nearly four decades.</p><p>Economists polled by Reuters had forecast a CPI gain of 0.4% for December and 7.0% on a year-on-year basis.</p><p>&#34;Investors were bracing for even hotter in inflation than what we actually saw. As bad as the number is and as much inflationary pressure that&#39;s in the economy there was a little relief in that,&#34; said Anthony Saglimbene, Ameriprise Financial&#39;s global market strategist in Troy, Michigan.</p><p>&#34;Today&#39;s inflation report validates the Fed trajectory and means they don&#39;t have to be any more aggressive than is already priced in.&#34;</p><p>The central bank&#39;s plan for easing accommodation to fight inflation includes raising interest rates, which analysts expect to start as soon as March, as well as tapering its bond buying program and reducing its asset holdings.</p><p>For most stock sectors it also helped that longer-dated U.S. Treasury yields dipped on Wednesday. In recent weeks, sharp gains in the U.S. 10-year yield had weighed on stocks, particularly in rate-sensitive growth sectors like technology.</p><p>&#34;The fact that bond market yields are standing down is probably a signal for equity investors to take on a little more risk today,&#34; said Jack Ablin, chief investment officer at Cresset Capital Management in Chicago.</p><p>But with the small cap Russell 2000 index underperforming to end down 0.82%, Ablin saw some caution.</p><p>&#34;Equity investors still want quality. It&#39;s not a free-for-all,&#34; Ablin said.</p><p>The Dow Jones Industrial Average rose 38.3 points, or 0.11%, to 36,290.32, the S&amp;P 500 gained 13.28 points, or 0.28%, to 4,726.35 and the Nasdaq Composite added 34.94 points, or 0.23%, to 15,188.39.</p><p>The S&amp;P&#39;s top sector gainers of the day were materials, up almost 1%, consumer discretionary, up 0.6% and technology which rose 0.4%.</p><p>Growth and technology stocks have been staging a comeback this week, with investors watching a variety of metrics to decide whether to buy the rally or brace for more declines.</p><p>Also on the watchlist for this week is the unofficial kick-off of the fourth quarter earnings season with JPMorgan Chase &amp; Co, CitigroupInc and Morgan Stanley due to report their results on Friday.</p><p>The Dow&#39;s biggest drag for the day was Goldman Sachs, which fell 3% and Morgan Stanley fell 2.7% on the day as their smaller rival Jefferies fell 9% after it missed quarterly earnings expectations.</p><p>Both Goldman and Morgan Stanley, like Jefferies depend heavily on their capital markets business. Both Morgan Stanley and Goldman were also in the top five biggest drags on the S&amp;P 500 on the day. However, the broader banking sector, which includes more traditional lenders, rose 0.3% on Wednesday.</p><p>In sectors like air travel, however, surging cases of the Omicron variant of the coronavirus could dampen earnings expectations, with analysts at Bank of America reckoning that the pandemic&#39;s impact on corporate travel is the biggest risk to the airline industry.</p><p>The healthcare index, was weighed down by shares of drugmaker Eli Lilly, which closed down 2.4% and was the biggest single weight on the S&amp;P, and Biogen, which lost 6.7%.</p><p>The U.S. government Medicare program said that while it plans to cover Biogen&#39;s Aduhelm Alzheimer treatment it will require patients to be enrolled in a clinical trial, limiting access to the medication. This could also impact Eli Lilly, which is developing similar drugs.</p><p>The biggest boosts to the S&amp;P on the day wereTeslaup 3.9% ahead of Microsoft Google parent Alphabet, which both rose more than 1%.</p><p>Advancing issues outnumbered declining ones on the NYSE by a 1.26-to-1 ratio; on Nasdaq, a 1.37-to-1 ratio favored decliners.</p><p>The S&amp;P 500 posted 38 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 60 new highs and 137 new lows.</p><p>On U.S. exchanges 10.251 billion shares changed hands compared with the 10.496 billion average for the last 20 sessions.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Closes Higher as Inflation Data Supports Fed Bets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Closes Higher as Inflation Data Supports Fed Bets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 07:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/ETFs/Wall+Street+closes+higher+as+inflation+data+supports+Fed+bets/19451289.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. stock indexes rose on Wednesday after data showed that while U.S. inflation was at its highest in decades, it largely met economists' expectations, cooling some fears that the Federal Reserve ...</p>\n\n<a href=\"https://www.streetinsider.com/ETFs/Wall+Street+closes+higher+as+inflation+data+supports+Fed+bets/19451289.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.streetinsider.com/ETFs/Wall+Street+closes+higher+as+inflation+data+supports+Fed+bets/19451289.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190696876","content_text":"U.S. stock indexes rose on Wednesday after data showed that while U.S. inflation was at its highest in decades, it largely met economists' expectations, cooling some fears that the Federal Reserve would have to pull back support even more forcibly than already expected.Ten out of the 11 major S&P sectors finished higher after the news with the S&P 500 and the Nasdaq outperforming the Dow as growth stocks outperformed value.Data from the Labor Department showed the consumer price index (CPI) increased 0.5% last month after rising 0.8% in November, while in the 12 months through December, the CPI surged 7.0% to its highest year-on-year rise in nearly four decades.Economists polled by Reuters had forecast a CPI gain of 0.4% for December and 7.0% on a year-on-year basis.\"Investors were bracing for even hotter in inflation than what we actually saw. As bad as the number is and as much inflationary pressure that's in the economy there was a little relief in that,\" said Anthony Saglimbene, Ameriprise Financial's global market strategist in Troy, Michigan.\"Today's inflation report validates the Fed trajectory and means they don't have to be any more aggressive than is already priced in.\"The central bank's plan for easing accommodation to fight inflation includes raising interest rates, which analysts expect to start as soon as March, as well as tapering its bond buying program and reducing its asset holdings.For most stock sectors it also helped that longer-dated U.S. Treasury yields dipped on Wednesday. In recent weeks, sharp gains in the U.S. 10-year yield had weighed on stocks, particularly in rate-sensitive growth sectors like technology.\"The fact that bond market yields are standing down is probably a signal for equity investors to take on a little more risk today,\" said Jack Ablin, chief investment officer at Cresset Capital Management in Chicago.But with the small cap Russell 2000 index underperforming to end down 0.82%, Ablin saw some caution.\"Equity investors still want quality. It's not a free-for-all,\" Ablin said.The Dow Jones Industrial Average rose 38.3 points, or 0.11%, to 36,290.32, the S&P 500 gained 13.28 points, or 0.28%, to 4,726.35 and the Nasdaq Composite added 34.94 points, or 0.23%, to 15,188.39.The S&P's top sector gainers of the day were materials, up almost 1%, consumer discretionary, up 0.6% and technology which rose 0.4%.Growth and technology stocks have been staging a comeback this week, with investors watching a variety of metrics to decide whether to buy the rally or brace for more declines.Also on the watchlist for this week is the unofficial kick-off of the fourth quarter earnings season with JPMorgan Chase & Co, CitigroupInc and Morgan Stanley due to report their results on Friday.The Dow's biggest drag for the day was Goldman Sachs, which fell 3% and Morgan Stanley fell 2.7% on the day as their smaller rival Jefferies fell 9% after it missed quarterly earnings expectations.Both Goldman and Morgan Stanley, like Jefferies depend heavily on their capital markets business. Both Morgan Stanley and Goldman were also in the top five biggest drags on the S&P 500 on the day. However, the broader banking sector, which includes more traditional lenders, rose 0.3% on Wednesday.In sectors like air travel, however, surging cases of the Omicron variant of the coronavirus could dampen earnings expectations, with analysts at Bank of America reckoning that the pandemic's impact on corporate travel is the biggest risk to the airline industry.The healthcare index, was weighed down by shares of drugmaker Eli Lilly, which closed down 2.4% and was the biggest single weight on the S&P, and Biogen, which lost 6.7%.The U.S. government Medicare program said that while it plans to cover Biogen's Aduhelm Alzheimer treatment it will require patients to be enrolled in a clinical trial, limiting access to the medication. This could also impact Eli Lilly, which is developing similar drugs.The biggest boosts to the S&P on the day wereTeslaup 3.9% ahead of Microsoft Google parent Alphabet, which both rose more than 1%.Advancing issues outnumbered declining ones on the NYSE by a 1.26-to-1 ratio; on Nasdaq, a 1.37-to-1 ratio favored decliners.The S&P 500 posted 38 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 60 new highs and 137 new lows.On U.S. exchanges 10.251 billion shares changed hands compared with the 10.496 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006789558,"gmtCreate":1641852650780,"gmtModify":1676533653193,"author":{"id":"4104063855005830","authorId":"4104063855005830","name":"LimLK","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104063855005830","authorIdStr":"4104063855005830"},"themes":[],"htmlText":"Like roller coasters having up and down with unpredictable changes&nbsp;","listText":"Like roller coasters having up and down with unpredictable changes&nbsp;","text":"Like roller coasters having up and down with unpredictable changes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006789558","repostId":"1199490797","repostType":4,"repost":{"id":"1199490797","kind":"news","pubTimestamp":1641828722,"share":"https://ttm.financial/m/news/1199490797?lang=&edition=fundamental","pubTime":"2022-01-10 23:32","market":"us","language":"en","title":"Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky","url":"https://stock-news.laohu8.com/highlight/detail?id=1199490797","media":"Barrons","summary":"Who needs parody cryptocurrency when car stocks are this exciting?","content":"<html><head></head><body><p>Who needs parody cryptocurrency when car stocks are this exciting? Ford Motor, General Motors, Tesla, and Rivian Automotive each had price swings of more than 10% during the first trading week of the year. This, after some heady gains for the group last year.</p><p>Predicting performance from here won’t be easy. I recently spoke with one analyst who says Tesla stock (ticker: TSLA) is headed to $1,400, and another who says $67. You know what they say: Sometimes you have to agree to disagree by a factor of 20.</p><p>Tesla made the first big move, jumping 13.5% on Monday after the company reported fourth-quarter deliveries of 308,600 vehicles, trouncing estimates and its own record. Next, Ford (F) gained 11.7% on Tuesday after it announced that it would raise production of its first electric pickup, the F-150 Lightning, to 150,000 units a year.</p><p>By that point in the week, General Motors stock (GM) was already up 12% in anticipation of its Chevy Silverado electric pickup truck unveiling, planned for Wednesday at the Consumer Electronics Show. But on the day of the announcement, shares slipped. Maybe investors were disappointed in the delivery timing, or maybe it was because the broad market tanked on signs that interest rates could rise sooner than expected.</p><p>What the Ford and Chevy pickups have in common is that they will target workers as well as suburban preeners in unblemished Carhartt jackets. Early versions will be priced around $40,000 and $100,000.</p><p>The Chevy wins on electric specs—longer battery range and faster charging. But Ford wins on bringing its truck to market this spring. Chevy buyers will have to wait until spring 2023 for the cheaper truck and fall 2023 for the decked-out one. GM will also debut electric Chevy sport utility vehicles in 2023, including an Equinox that will start at $30,000.</p><p>Pickup trucks could be the key to America’s electric-vehicle uptake. Last year, EVs hit an estimated 4% of total U.S. sales, up from 2%. But Europe and China are well ahead, with penetration rates in the low teens. Americans have so far had few electric choices for the types of vehicles they like to buy. Last year, the Ford F-150 led U.S. new-vehicle sales, as always. The only surprise was that the Ram 1500 pickup pulled ahead of the Chevy Silverado 1500 to be No. 2.</p><p>An electric Ram will take until 2024, according to owner Stellantis (STLA), a roll-up of American, Italian, and French brands. Start-up Rivian (RIVN) says it will ship electric pickups this year, but that stock slid 11% this past Wednesday after early backer Amazon.com (AMZN) said it’s putting in an order with Ram for delivery trucks. Tesla’s Cybertruck was expected last year, but has been delayed.</p><p>Pent-up vehicle demand, meanwhile, suggests that a boom is coming. Amid shortages last year, U.S. light-vehicle sales were an estimated 15.1 million units, versus closer to 17 million a year before the pandemic. Average transaction prices have soared 30% from prepandemic levels, and incentives as a percentage of prices are at record lows.</p><p>This year, expect unit sales to rise only modestly, but by next year, when showrooms are full and pricing has eased, units could jump to 18 million, Credit Suisse says. EV penetration in the U.S. will double again this year to 8%, and top 50% by 2030, it adds.</p><p>One risk for legacy car makers is that they will run to stand still—that they must ramp up EV units with low profit margins for now to offset coming losses in high-margin gasoline models.</p><p>On the other hand, car makers could shift capacity from gasoline vehicles to electric ones ahead of customers’ willingness to make the switch. That could leave gas vehicles with high prices and profit margins, creating a long, lucrative “farewell tour,” as Morgan Stanley analyst Adam Jonas puts it.</p><p>Valuations appear undemanding. Ford goes for 12 times projected earnings, despite doubling in price last year. GM sells for nine times.</p><p>The bull case on Tesla is that it will do big things in both cars and adjacent markets. Philippe Houchois, who covers the stock for Jefferies, sees 35% upside from recent levels, to $1,400. Tesla lags behind legacy rivals on things like build quality and finish, but those are solvable problems, he says. It leads on software, batteries, and autonomy, which are durable advantages. He sees Tesla using software to extend the usefulness and profit potential of vehicles.</p><p>Most versions of the Tesla bear case assume that the company will do well in cars, but not well enough to justify a market value above $1 trillion. For example, J.P. Morgan’s Ryan Brinkman calls his price target of $295 “not ungenerous,” even though it implies a 70% stock plunge, because it values Tesla slightly ahead of world leader Toyota Motor (TM), despite producing a tenth as many cars for now.</p><p>Then there’s Gordon Johnson. He worked at large investment banks before starting GLJ Research, where he covers 20 stocks. He’s bullish on uranium stocks and bearish on cannabis, but all anyone wants to talk about, he says, is his $67 price target on Tesla. “I’ve gotten death threats,” he says. “Now I don’t even answer the phone when I have unknown calls.”</p><p>In Johnson’s view, there’s no reason to assume Tesla will do well in adjacent businesses. “You could take McDonald’s and say they’re going to start selling Nikes and chairs and pianos and add those valuations,” he says. In cars, he calculates that the stock price implies a production ramp-up that no car maker could achieve. “Selling cars is not selling iPhones or shirts,” he says.</p><p>If Tesla’s three-year stock gain of nearly 1,400% has shaken Johnson’s confidence, it doesn’t show. After walking me through his valuation model, he said he’s concerned that his price target might be too high.</p></body></html>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tesla Stock Headed to $1,400 or $67? Why Predicting Auto Makers’ Performance Is Tricky\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-10 23:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/tesla-ford-rivian-gm-stock-51641597012?mod=mw_quote_news><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Who needs parody cryptocurrency when car stocks are this exciting? Ford Motor, General Motors, Tesla, and Rivian Automotive each had price swings of more than 10% during the first trading week of the ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/tesla-ford-rivian-gm-stock-51641597012?mod=mw_quote_news\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","F":"福特汽车","RIVN":"Rivian Automotive, Inc.","TSLA":"特斯拉"},"source_url":"https://www.marketwatch.com/articles/tesla-ford-rivian-gm-stock-51641597012?mod=mw_quote_news","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1199490797","content_text":"Who needs parody cryptocurrency when car stocks are this exciting? Ford Motor, General Motors, Tesla, and Rivian Automotive each had price swings of more than 10% during the first trading week of the year. This, after some heady gains for the group last year.Predicting performance from here won’t be easy. I recently spoke with one analyst who says Tesla stock (ticker: TSLA) is headed to $1,400, and another who says $67. You know what they say: Sometimes you have to agree to disagree by a factor of 20.Tesla made the first big move, jumping 13.5% on Monday after the company reported fourth-quarter deliveries of 308,600 vehicles, trouncing estimates and its own record. Next, Ford (F) gained 11.7% on Tuesday after it announced that it would raise production of its first electric pickup, the F-150 Lightning, to 150,000 units a year.By that point in the week, General Motors stock (GM) was already up 12% in anticipation of its Chevy Silverado electric pickup truck unveiling, planned for Wednesday at the Consumer Electronics Show. But on the day of the announcement, shares slipped. Maybe investors were disappointed in the delivery timing, or maybe it was because the broad market tanked on signs that interest rates could rise sooner than expected.What the Ford and Chevy pickups have in common is that they will target workers as well as suburban preeners in unblemished Carhartt jackets. Early versions will be priced around $40,000 and $100,000.The Chevy wins on electric specs—longer battery range and faster charging. But Ford wins on bringing its truck to market this spring. Chevy buyers will have to wait until spring 2023 for the cheaper truck and fall 2023 for the decked-out one. GM will also debut electric Chevy sport utility vehicles in 2023, including an Equinox that will start at $30,000.Pickup trucks could be the key to America’s electric-vehicle uptake. Last year, EVs hit an estimated 4% of total U.S. sales, up from 2%. But Europe and China are well ahead, with penetration rates in the low teens. Americans have so far had few electric choices for the types of vehicles they like to buy. Last year, the Ford F-150 led U.S. new-vehicle sales, as always. The only surprise was that the Ram 1500 pickup pulled ahead of the Chevy Silverado 1500 to be No. 2.An electric Ram will take until 2024, according to owner Stellantis (STLA), a roll-up of American, Italian, and French brands. Start-up Rivian (RIVN) says it will ship electric pickups this year, but that stock slid 11% this past Wednesday after early backer Amazon.com (AMZN) said it’s putting in an order with Ram for delivery trucks. Tesla’s Cybertruck was expected last year, but has been delayed.Pent-up vehicle demand, meanwhile, suggests that a boom is coming. Amid shortages last year, U.S. light-vehicle sales were an estimated 15.1 million units, versus closer to 17 million a year before the pandemic. Average transaction prices have soared 30% from prepandemic levels, and incentives as a percentage of prices are at record lows.This year, expect unit sales to rise only modestly, but by next year, when showrooms are full and pricing has eased, units could jump to 18 million, Credit Suisse says. EV penetration in the U.S. will double again this year to 8%, and top 50% by 2030, it adds.One risk for legacy car makers is that they will run to stand still—that they must ramp up EV units with low profit margins for now to offset coming losses in high-margin gasoline models.On the other hand, car makers could shift capacity from gasoline vehicles to electric ones ahead of customers’ willingness to make the switch. That could leave gas vehicles with high prices and profit margins, creating a long, lucrative “farewell tour,” as Morgan Stanley analyst Adam Jonas puts it.Valuations appear undemanding. Ford goes for 12 times projected earnings, despite doubling in price last year. GM sells for nine times.The bull case on Tesla is that it will do big things in both cars and adjacent markets. Philippe Houchois, who covers the stock for Jefferies, sees 35% upside from recent levels, to $1,400. Tesla lags behind legacy rivals on things like build quality and finish, but those are solvable problems, he says. It leads on software, batteries, and autonomy, which are durable advantages. He sees Tesla using software to extend the usefulness and profit potential of vehicles.Most versions of the Tesla bear case assume that the company will do well in cars, but not well enough to justify a market value above $1 trillion. For example, J.P. Morgan’s Ryan Brinkman calls his price target of $295 “not ungenerous,” even though it implies a 70% stock plunge, because it values Tesla slightly ahead of world leader Toyota Motor (TM), despite producing a tenth as many cars for now.Then there’s Gordon Johnson. He worked at large investment banks before starting GLJ Research, where he covers 20 stocks. He’s bullish on uranium stocks and bearish on cannabis, but all anyone wants to talk about, he says, is his $67 price target on Tesla. “I’ve gotten death threats,” he says. “Now I don’t even answer the phone when I have unknown calls.”In Johnson’s view, there’s no reason to assume Tesla will do well in adjacent businesses. “You could take McDonald’s and say they’re going to start selling Nikes and chairs and pianos and add those valuations,” he says. In cars, he calculates that the stock price implies a production ramp-up that no car maker could achieve. “Selling cars is not selling iPhones or shirts,” he says.If Tesla’s three-year stock gain of nearly 1,400% has shaken Johnson’s confidence, it doesn’t show. After walking me through his valuation model, he said he’s concerned that his price target might be too high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006544944,"gmtCreate":1641798664090,"gmtModify":1676533649036,"author":{"id":"4104063855005830","authorId":"4104063855005830","name":"LimLK","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104063855005830","authorIdStr":"4104063855005830"},"themes":[],"htmlText":"Hope we can have an vaccine for&nbsp;all variants&nbsp;to last longer rather than many jabs within 1 year","listText":"Hope we can have an vaccine for&nbsp;all variants&nbsp;to last longer rather than many jabs within 1 year","text":"Hope we can have an vaccine for all variants to last longer rather than many jabs within 1 year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006544944","repostId":"2202244067","repostType":4,"repost":{"id":"2202244067","kind":"highlight","pubTimestamp":1641797175,"share":"https://ttm.financial/m/news/2202244067?lang=&edition=fundamental","pubTime":"2022-01-10 14:46","market":"us","language":"en","title":"3 Big FDA Approvals to Watch for in Q1 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2202244067","media":"Motley Fool","summary":"Some of the world's biggest drugmakers have important dates with the FDA coming up soon.","content":"<html><head></head><body><p>Get ready for a deluge of important approval decisions. This year, before April showers get a chance to bring any May flowers, the FDA is expected to make a slew of important approval decisions.</p><p>Cancer patients in the U.S. could get some important new treatment options. Shares of the companies involved could put up big gains if the agency delivers the approval decisions investors are hoping for.</p><p>Big FDA decisions coming up in the first quarter for <b>Bristol Myers Squibb</b> (NYSE:BMY), <b>Eli Lilly</b> (NYSE:LLY) <b>AstraZeneca</b> (NASDAQ:AZN), and <b>Merck</b> (NYSE:MRK) could send their share prices soaring. Here&#39;s what to look for.</p><h2>Bristol Myers Squibb: Relatlimab</h2><p>Shares of Bristol Myers Squibb have gained around 17% since hitting a 52-week low in November. An FDA approval for a new type of cancer immunotherapy could push this pharma stock even higher.</p><p>In September, the FDA began a priority review of Bristol Myers Squibb&#39;s application for an all-new type of cancer immunotherapy called relatlimab. This is an antibody that prevents tumor cells from exploiting LAG-3, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many checkpoints that normally prevent the immune system from accidentally destroying healthy tissue. The FDA expects to issue an approval decision from this all-new checkpoint inhibitor on or before March 19.</p><p>Opdivo is another checkpoint inhibitor from Bristol Myers Squibb that acts on the PD-1 checkpoint. Opdivo is extremely effective for patients who respond to it, but far too many don&#39;t respond at all.</p><p>In the study underpinning its application, adding relatlimab to Opdivo reduced melanoma patients&#39; risk of disease worsening or death by 25% compared with treatment with Opdivio on its own. Unfortunately, side effects severe enough to warrant hospitalization were reported among 18.9% of patients who received the combination compared to 9.7% of those who received Opdivo on its own.</p><p>The questionable safety-to-benefit ratio of the relatlimab plus Opdivo combo isn&#39;t necessarily bad. That said, it could persuade the FDA to wait and see if adding relatlimab to Opdivo improves these patients&#39; overall chances of long-term survival.</p><h2>Eli Lilly and Innovent: Sintilimab</h2><p>Smart partnering decisions helped make Eli Lilly the best-performing pharmaceutical stock of the past five years. A licensing agreement with Innovent, one of the most successful biotechnology companies in China, could help Lilly stay on top for the next five years.</p><p>This March, the FDA is expected to make an approval decision regarding sintilimab, a PD-1 inhibitor that is already successful in China under the brand name Tyvyt. Pivotal studies run in China provided strong evidence of safety and efficacy, but Eli Lilly might have to run a large and expensive pivotal trial in the U.S. to satisfy the FDA.</p><p>The agency doesn&#39;t have a  policy that says U.S. trials are necessary before it will approve a new cancer drug. Instead, agency officials have been vocal about the need for results that are generalizable to the U.S. population.</p><p>On Feb. 10, 2021, the FDA will hold an advisory meeting to see what independent experts have to say about the available data. It doesn&#39;t seem likely, but it will have huge implications for the entire industry if Tyvyt can earn U.S. approval without more time and domestic investment.</p><h2>AstraZeneca and Merck: Lynparza</h2><p>Since earning first approval in 2014 to treat ovarian cancer, Lynparza sales have grown to an annualized $2.4 billion for AstraZeneca and around $980 million for its oncology collaboration partner Merck. An expansion to treat HER2-negative breast cancer patients after they&#39;ve had chemotherapy has been pushing Lynparza sales higher since 2018.</p><p>Before the end of the first quarter, the FDA could approve Lynparza to treat the much larger population of HER2-negative breast cancer patients following their first surgery to prevent the risk of recurrence. Recurrence prevention treatments, called adjuvants are extremely valuable because these patients tend to keep taking them for a very long time.</p><p>During the phase 3 trial supporting Lynparza&#39;s potential label expansion to the adjuvant setting for HER2-negative breast cancer, it reduced patients&#39; risk of disease recurrence by 42% compared to a placebo.</p><p>At less than $2.2 billion in the first nine months of 2021, sales of AstraZeneca&#39;s COVID-19 vaccine have been a little dissapointing. An expansion to the adjuvant setting for Lynparza, though, could go a long way to help investors feel better about the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Big FDA Approvals to Watch for in Q1 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Big FDA Approvals to Watch for in Q1 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-10 14:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/09/3-big-fda-approvals-to-watch-in-q1-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Get ready for a deluge of important approval decisions. This year, before April showers get a chance to bring any May flowers, the FDA is expected to make a slew of important approval decisions.Cancer...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/09/3-big-fda-approvals-to-watch-in-q1-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4516":"特朗普概念","BK4007":"制药","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4532":"文艺复兴科技持仓","AZN":"阿斯利康","MRK":"默沙东","BMY":"施贵宝","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","LLY":"礼来","BK4550":"红杉资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/09/3-big-fda-approvals-to-watch-in-q1-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2202244067","content_text":"Get ready for a deluge of important approval decisions. This year, before April showers get a chance to bring any May flowers, the FDA is expected to make a slew of important approval decisions.Cancer patients in the U.S. could get some important new treatment options. Shares of the companies involved could put up big gains if the agency delivers the approval decisions investors are hoping for.Big FDA decisions coming up in the first quarter for Bristol Myers Squibb (NYSE:BMY), Eli Lilly (NYSE:LLY) AstraZeneca (NASDAQ:AZN), and Merck (NYSE:MRK) could send their share prices soaring. Here's what to look for.Bristol Myers Squibb: RelatlimabShares of Bristol Myers Squibb have gained around 17% since hitting a 52-week low in November. An FDA approval for a new type of cancer immunotherapy could push this pharma stock even higher.In September, the FDA began a priority review of Bristol Myers Squibb's application for an all-new type of cancer immunotherapy called relatlimab. This is an antibody that prevents tumor cells from exploiting LAG-3, one of many checkpoints that normally prevent the immune system from accidentally destroying healthy tissue. The FDA expects to issue an approval decision from this all-new checkpoint inhibitor on or before March 19.Opdivo is another checkpoint inhibitor from Bristol Myers Squibb that acts on the PD-1 checkpoint. Opdivo is extremely effective for patients who respond to it, but far too many don't respond at all.In the study underpinning its application, adding relatlimab to Opdivo reduced melanoma patients' risk of disease worsening or death by 25% compared with treatment with Opdivio on its own. Unfortunately, side effects severe enough to warrant hospitalization were reported among 18.9% of patients who received the combination compared to 9.7% of those who received Opdivo on its own.The questionable safety-to-benefit ratio of the relatlimab plus Opdivo combo isn't necessarily bad. That said, it could persuade the FDA to wait and see if adding relatlimab to Opdivo improves these patients' overall chances of long-term survival.Eli Lilly and Innovent: SintilimabSmart partnering decisions helped make Eli Lilly the best-performing pharmaceutical stock of the past five years. A licensing agreement with Innovent, one of the most successful biotechnology companies in China, could help Lilly stay on top for the next five years.This March, the FDA is expected to make an approval decision regarding sintilimab, a PD-1 inhibitor that is already successful in China under the brand name Tyvyt. Pivotal studies run in China provided strong evidence of safety and efficacy, but Eli Lilly might have to run a large and expensive pivotal trial in the U.S. to satisfy the FDA.The agency doesn't have a  policy that says U.S. trials are necessary before it will approve a new cancer drug. Instead, agency officials have been vocal about the need for results that are generalizable to the U.S. population.On Feb. 10, 2021, the FDA will hold an advisory meeting to see what independent experts have to say about the available data. It doesn't seem likely, but it will have huge implications for the entire industry if Tyvyt can earn U.S. approval without more time and domestic investment.AstraZeneca and Merck: LynparzaSince earning first approval in 2014 to treat ovarian cancer, Lynparza sales have grown to an annualized $2.4 billion for AstraZeneca and around $980 million for its oncology collaboration partner Merck. An expansion to treat HER2-negative breast cancer patients after they've had chemotherapy has been pushing Lynparza sales higher since 2018.Before the end of the first quarter, the FDA could approve Lynparza to treat the much larger population of HER2-negative breast cancer patients following their first surgery to prevent the risk of recurrence. Recurrence prevention treatments, called adjuvants are extremely valuable because these patients tend to keep taking them for a very long time.During the phase 3 trial supporting Lynparza's potential label expansion to the adjuvant setting for HER2-negative breast cancer, it reduced patients' risk of disease recurrence by 42% compared to a placebo.At less than $2.2 billion in the first nine months of 2021, sales of AstraZeneca's COVID-19 vaccine have been a little dissapointing. An expansion to the adjuvant setting for Lynparza, though, could go a long way to help investors feel better about the years ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006889665,"gmtCreate":1641688527096,"gmtModify":1676533639406,"author":{"id":"4104063855005830","authorId":"4104063855005830","name":"LimLK","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104063855005830","authorIdStr":"4104063855005830"},"themes":[],"htmlText":"Hope Covid will end this year","listText":"Hope Covid will end this year","text":"Hope Covid will end this year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006889665","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://ttm.financial/m/news/1134509683?lang=&edition=fundamental","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008449197,"gmtCreate":1641515833733,"gmtModify":1676533623724,"author":{"id":"4104063855005830","authorId":"4104063855005830","name":"LimLK","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104063855005830","authorIdStr":"4104063855005830"},"themes":[],"htmlText":"Hope this Covid-19 and&nbsp;whatever variants are&nbsp;over soon!&nbsp;","listText":"Hope this Covid-19 and&nbsp;whatever variants are&nbsp;over soon!&nbsp;","text":"Hope this Covid-19 and whatever variants are over soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008449197","repostId":"2201295136","repostType":4,"repost":{"id":"2201295136","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1641513038,"share":"https://ttm.financial/m/news/2201295136?lang=&edition=fundamental","pubTime":"2022-01-07 07:50","market":"us","language":"en","title":"J&J says its single dose protects against breakthrough COVID-19 for up to 6 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2201295136","media":"Reuters","summary":"Jan 6 (Reuters) - Johnson & Johnson said on Thursday that a real-world study showed its single shot ","content":"<html><head></head><body><p>Jan 6 (Reuters) - Johnson &amp; Johnson said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.</p><p>The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.</p><p>J&amp;J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech&#39;s as well as Moderna.</p><p>No waning of protection was found for ICU admissions for all the three vaccines, J&amp;J said.</p><p>The company said the study was carried out by collecting claims and laboratory data covering 168 million people.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J says its single dose protects against breakthrough COVID-19 for up to 6 months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J says its single dose protects against breakthrough COVID-19 for up to 6 months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-07 07:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Jan 6 (Reuters) - Johnson &amp; Johnson said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.</p><p>The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.</p><p>J&amp;J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech&#39;s as well as Moderna.</p><p>No waning of protection was found for ICU admissions for all the three vaccines, J&amp;J said.</p><p>The company said the study was carried out by collecting claims and laboratory data covering 168 million people.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201295136","content_text":"Jan 6 (Reuters) - Johnson & Johnson said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna.No waning of protection was found for ICU admissions for all the three vaccines, J&J said.The company said the study was carried out by collecting claims and laboratory data covering 168 million people.","news_type":1},"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008854060,"gmtCreate":1641425500191,"gmtModify":1676533612921,"author":{"id":"4104063855005830","authorId":"4104063855005830","name":"LimLK","avatar":"https://static.tigerbbs.com/82b0ff1010d6b29f09a9ec35c2534921","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104063855005830","authorIdStr":"4104063855005830"},"themes":[],"htmlText":"Stay safe everyone and hope this will be over soon🙏","listText":"Stay safe everyone and hope this will be over soon🙏","text":"Stay safe everyone and hope this will be over soon🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008854060","repostId":"2201255642","repostType":4,"repost":{"id":"2201255642","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1641424473,"share":"https://ttm.financial/m/news/2201255642?lang=&edition=fundamental","pubTime":"2022-01-06 07:14","market":"us","language":"en","title":"Walmart halves paid leave for COVID-positive workers","url":"https://stock-news.laohu8.com/highlight/detail?id=2201255642","media":"Reuters","summary":"Jan 5 (Reuters) - Walmart Inc workers in the United States who must isolate or who have tested posit","content":"<html><head></head><body><p>Jan 5 (Reuters) - Walmart Inc workers in the United States who must isolate or who have tested positive for COVID-19 will receive <a href=\"https://laohu8.com/S/AONE.U\">one</a> week of paid leave instead of two under a new policy that aligns with a change in U.S. health guidance.</p><p>A memo, seen by Reuters, sent on Tuesday to U.S. hourly store employees and long-haul drivers said COVID-19 positive workers and those required to quarantine - by Walmart, a health care provider or a government agency - are eligible for one work week of paid time off.</p><p>The company&#39;s guidelines follow the U.S. Centers for Disease Control and Prevention&#39;s updated recommendations last week that people isolate for five days after a COVID-19 infection, instead of 10 days.</p><p>The retailer, the largest private employer in the United States with about 1.6 million workers, is among the first major retailers to reduce paid leave for COVID-19, and could serve as a bellwether for other major employers.</p><p>The move comes as a spike in COVID-19 cases is causing significant labor shortages across an industry that is already battling supply-chain snarls, product shortages, rising inflation and rocketing transportation costs.</p><p>A Walmart spokesperson confirmed the COVID-leave policy change. Workers who continue to be sick can potentially receive additional COVID-related pay for up to 26 weeks.</p><p>The spokesperson added that Walmart was asking corporate employees to work primarily from home until Jan. 30, rather than Jan. 10 previously announced.</p><p>The company operates 600 Sam&#39;s Club stores and more than 4,700 Walmart U.S. stores in the United States. On Monday, the company said it temporarily shut 60 stores in COVID-19 hot spots in December to sanitize them against the virus.</p><p>&#34;A lot of people don&#39;t want to come into work as they&#39;re either afraid or getting coronavirus,&#34; Peter Naughton, 46, a Walmart electronics salesperson in Baton Rouge and member of labor non-profit United for Respect. &#34;I can&#39;t afford not to come to work.&#34;</p><p>Like other mass retailers, Walmart has witnessed a boom in sales during the pandemic as more people shopped for groceries and home goods. The company raised its full-year annual sales and profit forecast in November but disappointed investors with higher labor and transportation costs that eroded margins.</p><p>The company&#39;s stock is nearly flat over the past one year compared to the broader S&amp;P 500 retailing index&#39;s 20.6% rise over the same period.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Walmart halves paid leave for COVID-positive workers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWalmart halves paid leave for COVID-positive workers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-06 07:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Jan 5 (Reuters) - Walmart Inc workers in the United States who must isolate or who have tested positive for COVID-19 will receive <a href=\"https://laohu8.com/S/AONE.U\">one</a> week of paid leave instead of two under a new policy that aligns with a change in U.S. health guidance.</p><p>A memo, seen by Reuters, sent on Tuesday to U.S. hourly store employees and long-haul drivers said COVID-19 positive workers and those required to quarantine - by Walmart, a health care provider or a government agency - are eligible for one work week of paid time off.</p><p>The company&#39;s guidelines follow the U.S. Centers for Disease Control and Prevention&#39;s updated recommendations last week that people isolate for five days after a COVID-19 infection, instead of 10 days.</p><p>The retailer, the largest private employer in the United States with about 1.6 million workers, is among the first major retailers to reduce paid leave for COVID-19, and could serve as a bellwether for other major employers.</p><p>The move comes as a spike in COVID-19 cases is causing significant labor shortages across an industry that is already battling supply-chain snarls, product shortages, rising inflation and rocketing transportation costs.</p><p>A Walmart spokesperson confirmed the COVID-leave policy change. Workers who continue to be sick can potentially receive additional COVID-related pay for up to 26 weeks.</p><p>The spokesperson added that Walmart was asking corporate employees to work primarily from home until Jan. 30, rather than Jan. 10 previously announced.</p><p>The company operates 600 Sam&#39;s Club stores and more than 4,700 Walmart U.S. stores in the United States. On Monday, the company said it temporarily shut 60 stores in COVID-19 hot spots in December to sanitize them against the virus.</p><p>&#34;A lot of people don&#39;t want to come into work as they&#39;re either afraid or getting coronavirus,&#34; Peter Naughton, 46, a Walmart electronics salesperson in Baton Rouge and member of labor non-profit United for Respect. &#34;I can&#39;t afford not to come to work.&#34;</p><p>Like other mass retailers, Walmart has witnessed a boom in sales during the pandemic as more people shopped for groceries and home goods. The company raised its full-year annual sales and profit forecast in November but disappointed investors with higher labor and transportation costs that eroded margins.</p><p>The company&#39;s stock is nearly flat over the past one year compared to the broader S&amp;P 500 retailing index&#39;s 20.6% rise over the same period.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WMT":"沃尔玛","BK4534":"瑞士信贷持仓","BK4155":"大卖场与超市","BK4504":"桥水持仓","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4532":"文艺复兴科技持仓"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201255642","content_text":"Jan 5 (Reuters) - Walmart Inc workers in the United States who must isolate or who have tested positive for COVID-19 will receive one week of paid leave instead of two under a new policy that aligns with a change in U.S. health guidance.A memo, seen by Reuters, sent on Tuesday to U.S. hourly store employees and long-haul drivers said COVID-19 positive workers and those required to quarantine - by Walmart, a health care provider or a government agency - are eligible for one work week of paid time off.The company's guidelines follow the U.S. Centers for Disease Control and Prevention's updated recommendations last week that people isolate for five days after a COVID-19 infection, instead of 10 days.The retailer, the largest private employer in the United States with about 1.6 million workers, is among the first major retailers to reduce paid leave for COVID-19, and could serve as a bellwether for other major employers.The move comes as a spike in COVID-19 cases is causing significant labor shortages across an industry that is already battling supply-chain snarls, product shortages, rising inflation and rocketing transportation costs.A Walmart spokesperson confirmed the COVID-leave policy change. Workers who continue to be sick can potentially receive additional COVID-related pay for up to 26 weeks.The spokesperson added that Walmart was asking corporate employees to work primarily from home until Jan. 30, rather than Jan. 10 previously announced.The company operates 600 Sam's Club stores and more than 4,700 Walmart U.S. stores in the United States. On Monday, the company said it temporarily shut 60 stores in COVID-19 hot spots in December to sanitize them against the virus.\"A lot of people don't want to come into work as they're either afraid or getting coronavirus,\" Peter Naughton, 46, a Walmart electronics salesperson in Baton Rouge and member of labor non-profit United for Respect. \"I can't afford not to come to work.\"Like other mass retailers, Walmart has witnessed a boom in sales during the pandemic as more people shopped for groceries and home goods. The company raised its full-year annual sales and profit forecast in November but disappointed investors with higher labor and transportation costs that eroded margins.The company's stock is nearly flat over the past one year compared to the broader S&P 500 retailing index's 20.6% rise over the same period.","news_type":1},"isVote":1,"tweetType":1,"viewCount":428,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}